We are investigating the safety and tolerability of a new treatment, ARGX-119, for adults with DOK7 Congenital Myasthenic Syndrome. This study aims to understand how well the treatment is tolerated in this specific group.
Health conditions and diseases that the clinical trial is designed to study and treat.
Congenital Myasthenic Syndrome (CMS) is a rare genetic disorder that affects the communication between nerves and muscles, leading to muscle weakness and fatigue. Symptoms can vary but often include muscle weakness that worsens with activity and improves with rest.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
